The U.S. Food and Drug Administration (FDA) has approved revumenib (Revuforj) for people with relapsed or refractory acute myeloid leukemia (AML) who have a specific mutation in the NPM1 gene. The approval applies to both adults and children 1 year and older who have no other effective treatment options.
Revuforj is the first menin inhibitor approved for this type of leukemia. It targets a molecular pathway that helps leukemia cells grow, offering a new precision therapy for patients whose disease has returned or not responded to prior treatments.
The approval was based on results from the AUGMENT-101 clinical trial, which included patients whose cancers carried the NPM1 mutation. In the study, 23 percent of patients achieved complete remission or near-complete remission, with some maintaining those responses for several months. Some patients who previously needed blood transfusions also became transfusion independent during treatment.
As with other targeted therapies, Revuforj may cause serious side effects, including a condition known as differentiation syndrome, heart rhythm changes, and potential risks to an unborn baby. Patients should discuss these risks and monitoring plans with their healthcare team.
Reference
